Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential.

Cherny E, Minko T

Open source

DOI
10.3390/pharmaceutics18091099
Published
2026 Sep 1
Container
Pharmaceutics
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics18091099,
  title = {Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential.},
  author = {Cherny E and Minko T},
  year = {2026},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics18091099},
  url = {https://doi.org/10.3390/pharmaceutics18091099}
}

RIS

TY  - JOUR
TI  - Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential.
AU  - Cherny E
AU  - Minko T
PY  - 2026
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics18091099
UR  - https://doi.org/10.3390/pharmaceutics18091099
ER  - 

APA

E, C., & T, M. (2026). Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics18091099

Source records